Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Food and Drug Administration has approved label changes for Viread to include new dose recommendations for patients with kidney impairment, a new warning about HIV'hepatitis B coinfection, dose recommendations for using Viread with Videx, and updated information on the drug's effects on the body's bones. The new label also says Viread can be taken with or without food. GlaxoSmithKline has warned health care providers that the combination of its anti-HIV drugs Epivir and Ziagen with Viread appears to be significantly less potent than other combinations of anti-HIV medications. Bristol-Myers Squibb has warned doctors that combining Reyataz, its new protease inhibitor, with Viread may result in a reduction in blood-based Reyataz levels by up to 40%, posing a risk for treatment failure. If the two drugs are used together, Reyataz should be boosted with Norvir. An experimental drug developed by Bristol-Myers Squibb, BMS-378806, has been shown in animal studies to be effective in preventing a key HIV protein from binding to a CD4-cell surface receptor. The drug is being developed as an HIV fusion inhibitor. Researchers at the University of Kentucky are developing a prescription patch that would deliver synthetic cannabinoids, the active ingredient in marijuana, through the skin to help ease nausea and stimulate appetite in AIDS and cancer patients. Australian company Starpharma has received FDA approval to begin U.S. human trials of VivaGel, a microbicide designed to prevent vaginal HIV transmission. A study in the July 25 issue of AIDS shows that intravaginal application of a gel containing the experimental nonnucleoside reverse transcriptase inhibitor TMC120, developed by Tibotec, was effective in preventing vaginal HIV infection in animals. A research letter in the July 25 issue of AIDS suggests that combining the protease inhibitors Kaletra and Fortovase could be effective as a cornerstone of a salvage therapy regimen for heavily treated HIV-positive adults. Once-daily dosing of Emtriva was as effective as twice-daily administration of Ziagen, according to a study presented at the International AIDS Society Conference on HIV Pathogenesis and Treatment. A study presented at the International AIDS Society Conference on HIV Pathogenesis and Treatment shows that a regimen containing Crixivan boosted by Norvir and two nucleoside reverse transcriptase inhibitors was an effective and welltolerated first-line therapy. A study presented at the International AIDS Society Conference on HIV Pathogenesis and Treatment shows that an antiretroviral regimen containing Sustiva outperforms a triple nucleoside regimen. Researchers at the Aaron Diamond AIDS Research Center have reported that viral loads of treatment-naive patients can be rapidly reduced to undetectable levels with a first-line regimen of Trizivir plus Sustiva. Most neurological side effects of Sustiva, including vivid dreams and sleep disturbances, are generally resolved after four weeks of treatment, according to a study presented at the International AIDS Society Conference on HIV Pathogenesis and Treatment. Two studies presented at the International AIDS Society Conference on HIV Pathogenesis and Treatment show that elevated cholesterol and triglyceride levels in treatment-experienced patients improve when anti-HIV drug regimens were changed to include Reyataz. A study in the August 15 edition of AIDS shows that switching from a nonnucleoside reverse transcriptase inhibitor'based regimen to Trizivir can result in significant lipid improvements without losing viral control. Researchers in Canada report that patients with advanced HIV disease are at a higher risk than others for eventually developing kidney problems linked with the use of Viread. Gilead Sciences has announced the recruitment of treatment-naive study subjects for a Phase III comparative study of a once-daily anti-HIV drug regimen containing its drugs Viread and Emtriva plus Sustiva to a twice-daily regimen. The trial will include 300 patients in the United States and Europe.
From our Sponsors
Most Popular
Lexi Love comes out as HIV+ after Trump deletes federal resources
January 23 2025 11:23 AM
Grindr is reminding us why jockstraps are so sexy and iconic
May 02 2025 5:36 PM
BREAKING NEWS: Trump admin moves to end federal HIV prevention programs
March 18 2025 6:10 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Tyler TerMeer vows to continue to fight for health care for all
January 28 2025 3:00 PM
Discover the power of Wellness in your life
March 26 2025 12:41 PM
Plus: Featured Video
Latest Stories
Dancer. Healer. Survivor. DéShaun Armbrister is all of the above
July 02 2025 8:23 PM
Two right-wing Supreme Court justices signal they may uphold access to PrEP and more
April 21 2025 4:10 PM
Broadway's best raise over $1 million for LGBTQ+ and HIV causes
April 03 2025 7:15 PM
Plus nominated for 2025 GLAAD Media Award
January 22 2025 12:42 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
BREAKING: Supreme Court rules to save free access to preventive care, including PrEP
June 27 2025 10:32 AM
1985: the year the AIDS crisis finally broke through the silence
June 26 2025 11:24 AM
Trump admin guts $258 million in funding for HIV vaccine research
June 03 2025 3:47 PM
500,000 Children at Risk: PEPFAR Funding Crisis
April 08 2025 3:51 PM
The Talk Season 5 premieres this spring with HIV guidance for the newly diagnosed
March 26 2025 1:00 PM
Jess King is here to help you live your happiest, healthiest life yet
March 24 2025 4:35 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
VIDEO: A man living with HIV discusses his journey to fatherhood
June 10 2025 4:58 PM
HRC holds 'die-in' to protest Trump health care cuts
April 28 2025 2:11 PM
Season 4 of The Switch on resilience & radical self-love returns this spring
March 26 2025 12:20 PM
Gerald Garth is keeping people of color happy and healthy through trying times
March 11 2025 3:38 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM